Kelly Jason R's Form 4 filing
Ginkgo Bioworks Holdings, Inc. (DNA) · filed Feb 7, 2023
- Accession no.
- 0001127602-23-003809
- Filed
- Feb 7, 2023
- Trade date
- Feb 3-6, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $645.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kelly Jason RCIK 0001845677 | Director, Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2023 | Class A Common Stock | SSaleDisposed | −156,383 | $2.13 | −$333,095.79 | 13,733,103 | Direct | |
| Feb 6, 2023 | Class A Common Stock | SSaleDisposed | −157,790 | $1.98 | −$312,424.2 | 13,575,313 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
CEO & Founder